Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are currently the first-line standard of care for patients with non-small cell lung cancer (NSCLC) that harbor EGFR mutations. Nevertheless, resistance to EGFR-TKIs is inevitable. In recent years, although immune checkpoint inhi...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Chinês |
| Julkaistu: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2023-12-01
|
| Sarja: | Chinese Journal of Lung Cancer |
| Aiheet: | |
| Linkit: | http://dx.doi.org/10.3779/j.issn.1009-3419.2023.106.26 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|